HZNP - ホライゾン・ファ―マ (Horizon Pharma plc) ホライゾン・ファ―マ

 HZNPのチャート


 HZNPの企業情報

symbol HZNP
会社名 Horizon Pharma Plc (ホライゾン・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ホライゾン・ファーマ(Horizon Pharma Public Limited Company)はバイオ医薬品会社である。同社は満たされていない医療ニーズに対処する差別化された接近可能な医薬品の特定・開発・取得・商業化に従事する。同社は希少疾病、リウマチ、プライマリケア事業セグメントを通じて11の医薬品を販売する。同社が販売する医薬品は、ACTIMMUNE(インターフェロンγ-1b)、BUPHENYL(フェニル酪酸ナトリウム)錠剤および粉末、DUEXIS(イブプロフェン/ファモチジン)、KRYSTEXXA(ペグロチナーゼ)、MIGERGOT(エルゴタミン酒石酸塩およびカフェイン坐剤)、2重量%のPENNSAID(ジクロフェナクナトリウム局所溶液)、またはPENNSAID 2%、PROCYSBI(酒石酸水素システアミン)遅延放出カプセル、QUINSAIR(エアロゾル化形態のレボフロキサシン)、RAVICTI(グリセロールフェニルブチラート)経口液体、RAYOS (プレドニゾン)遅延放出錠剤およびVIMOVO(ナプロキセン/エソメプラゾールマグネシウム)を含む。   ホライゾン・ファ―マはアイルランドのバイオ医薬品持株会社。関節炎、疼痛、炎症性疾患向けの医薬品を開発、販売する。主要製品はイブプロフェンとファモチジンを組み合わせた単一錠剤のDUEXIS、成人向けの関節リウマチ治療薬RAYOS/LODOTRA(米国内でRAYOS、米国外ではLODOTRAとして提供)、およびVIMOVOなど。   
本社所在地 Connaught House 1st Floor 1 Burlington Road Dublin 4 D04 C5Y6 IRL
代表者氏名 Timothy P. Walbert ティモシー・P・ウォルバーツ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +353 1-772-2100
設立年月日 38504
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 1010人
url www.horizonpharma.com
nasdaq_url https://www.nasdaq.com/symbol/hznp
adr_tso
EBITDA EBITDA(百万ドル) 89.14000
終値(lastsale) 18.16
時価総額(marketcap) 3025996042.08
時価総額 時価総額(百万ドル) 3177.629
売上高 売上高(百万ドル) 172.581
企業価値(EV) 企業価値(EV)(百万ドル) 4352.536
当期純利益 当期純利益(百万ドル) -375.58200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Horizon Pharma PLC revenues increased 3% to $526.7M. Net loss decreased 37% to $190.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development - Balancing val decrease of 78% to $37.3M (expense) Interest Expense - Net decrease of 3% to $61.5M (expense).

 HZNPのテクニカル分析


 HZNPのニュース

   Horizon Therapeutics Public Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/02/23 03:56:00 Stock Market Daily
Horizon Therapeutics Public announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase  2021/02/22 14:30:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the NANOS Annual Meeting.
   Dr Reddy's loses bid to invalidate Horizon arthritis drug patents  2021/02/18 00:09:56 Reuters
Indian generic drugmaker Dr Reddy's Laboratories Ltd has lost a bid to invalidate patents on Horizon Therapeutics Plc and Nuvo Pharmaceuticals Inc's arthritis drug Vimovo.
   Jefferies Stick to Their Buy Rating for Horizon Therapeutics By Investing.com  2021/02/17 20:25:16 Investing.com
Jefferies Stick to Their Buy Rating for Horizon Therapeutics
   This Is What Hedge Funds Bought And Sold In Q4: Complete 13F Summary  2021/02/17 02:10:00 Zero Hedge
This Is What Hedge Funds Bought And Sold In Q4: Complete 13F Summary In the aftermath of late January's massive short squeeze fireworks, 13F reporting season - which had lost much of its luster in recent years as hedge funds lost much of their impact in a centrally-planned world - was once again interesting, if only to find who had extra exposure to the January short-squeeze turmoil. Of course, we should caveat that as usual, all of the positions disclosed in today's round of 13Fs were stale by at least 45 days, and as such there has certainly been significant rotation out of the high beta and most shorted names in late January and early February. With that said, and as noted earlier , the big highlight was Warren Buffett’s Berkshire Hathaway which trimmed its Apple holding in the fourth quarter, while reporting formerly secret stakes in Verizon ($8.6BN), Chevron ($4.1BN) and Marsh & McLennan ($499MM). Berkshire's reduction in Apple stood in contrast to other positions investment funds revealed in regulatory filings for the quarter, which showed several favoring megacap tech companies according to Bloomberg which notes that Microsoft has been an early winner in 13F filings released so far as major hedge funds bought positions.
   Horizon Therapeutics Public Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/02/23 03:56:00 Stock Market Daily
Horizon Therapeutics Public announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase  2021/02/22 14:30:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the NANOS Annual Meeting.
   Dr Reddy's loses bid to invalidate Horizon arthritis drug patents  2021/02/18 00:09:56 Reuters
Indian generic drugmaker Dr Reddy's Laboratories Ltd has lost a bid to invalidate patents on Horizon Therapeutics Plc and Nuvo Pharmaceuticals Inc's arthritis drug Vimovo.
   Jefferies Stick to Their Buy Rating for Horizon Therapeutics By Investing.com  2021/02/17 20:25:16 Investing.com
Jefferies Stick to Their Buy Rating for Horizon Therapeutics
   This Is What Hedge Funds Bought And Sold In Q4: Complete 13F Summary  2021/02/17 02:10:00 Zero Hedge
This Is What Hedge Funds Bought And Sold In Q4: Complete 13F Summary In the aftermath of late January's massive short squeeze fireworks, 13F reporting season - which had lost much of its luster in recent years as hedge funds lost much of their impact in a centrally-planned world - was once again interesting, if only to find who had extra exposure to the January short-squeeze turmoil. Of course, we should caveat that as usual, all of the positions disclosed in today's round of 13Fs were stale by at least 45 days, and as such there has certainly been significant rotation out of the high beta and most shorted names in late January and early February. With that said, and as noted earlier , the big highlight was Warren Buffett’s Berkshire Hathaway which trimmed its Apple holding in the fourth quarter, while reporting formerly secret stakes in Verizon ($8.6BN), Chevron ($4.1BN) and Marsh & McLennan ($499MM). Berkshire's reduction in Apple stood in contrast to other positions investment funds revealed in regulatory filings for the quarter, which showed several favoring megacap tech companies according to Bloomberg which notes that Microsoft has been an early winner in 13F filings released so far as major hedge funds bought positions.
   Horizon Therapeutics has agreed to buy biotech company Viela Bio for $3 billion - We Beat the Broker  2021/02/02 23:15:00 We Beat the Broker
Horizon Therapeutics has agreed to buy biotech company Viela Bio for $3 billion, according to an announcement on Feb. 1. Shares of Horizon closed 6.3%
   Osteoarthritis Therapeutics Market worth $11.0 billion by 2025 - Leading Key Players are Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US)  2021/02/02 11:33:43 OpenPR
According to the new market research report "Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies),Purchasing Pattern (Prescription Drugs)-Global Forecast to 2025", published by MarketsandMarkets™, the global market is
   Viela Bio Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Viela Bio, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – VIE  2021/02/01 16:24:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether Viela Bio, Inc. (NASDAQ: VIE) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Viela Bio to Horizon Therapeutics plc for $53.00 per share in cash. On behalf of Viela Bio shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and infor
   Horizon Therapeutics To Buy Viela For $3.05B: What You Need To Know  2021/02/01 15:51:29 Benzinga
Horizon Therapeutics PLC (NASDAQ: HZNP ), a rare and rheumatic diseases drug company, announced a multibillion-dollar deal Monday to snap up Viela Bio Inc (NASDAQ: VIE ). What Happened: Horizon said it has entered into a definitive agreement to acquire Viela for $53 per share in cash, which represents a fully diluted equity value of about $3.05 billion, or about $2.67 billion net of Viela's cash and cash equivalents. The per-share value represented a premium of 52.8% over Viela's Friday closing price of $34.68. "Adding Viela's research and clinical development capabilities along with its deep, mid-stage biologics pipeline to our seasoned R&D and commercial teams, advances our transformation to an innovation-driven biotech company where we will build on the success of TEPEZZA and KRYSTEXXA to bolster our long-term growth trajectory," Horizon … Full story available on Benzinga.com
   AstraZeneca to divest Viela Bio stake  2021/02/01 13:44:11 Share Cast
AstraZeneca has agreed to divest its 26.7% stake in US biotechnology company Viela Bio as part of the latter’s proposed acquisition by Horizon Therapeutics.

 関連キーワード  (医薬品 米国株 ホライゾン・ファ―マ HZNP Horizon Pharma plc)

 twitter  (公式ツイッターやCEOツイッターなど)